Business Context and Reporting Period
This Form 8-K Current Report was filed by Synta Pharmaceuticals Corp. on April 11, 2014. The filing discloses the entry into a material definitive agreement involving a private placement of common stock. Note: The request metadata references "Madrigal Pharmaceuticals, Inc.," but the source text explicitly identifies the registrant as Synta Pharmaceuticals Corp.
Key Financial Metrics
- Transaction Type: Private placement of 1,250,000 shares of common stock.
- Purchase Price: $4.01 per share.
- Gross Proceeds: Approximately $5.01 million (1,250,000 shares x $4.01).
- Net Proceeds: Approximately $5.0 million after estimated offering expenses.
- Buyer: KFO Holdings LLC, an entity affiliated with Bruce Kovner, a director and the Company's largest stockholder.
- Ownership Impact: Mr. Kovner's beneficial ownership increased from approximately 31.7% to 32.7% following the transaction.
- Settlement Date: Expected on or before April 17, 2014.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics as this is a transaction-specific report rather than a periodic financial statement.
Material Changes
The primary material change is the increase in outstanding common stock and the corresponding increase in cash proceeds for the Company. There is no comparative period data provided in this filing to assess changes in operational metrics versus prior periods.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the description of the agreement is qualified by reference to the attached exhibits. The transaction was executed without a placement agent, underwriter, broker, or dealer.
Investor Verification Checklist
- Verify the final settlement date and actual net proceeds received.
- Review the Subscription Agreement (Exhibit 10.1) for any covenants or restrictions on the shares.
- Confirm the updated beneficial ownership percentage of Bruce Kovner in subsequent filings.
- Check the press release (Exhibit 99.1) for additional context on the use of proceeds.